Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Lilly's New Weight-Loss Pill Underperforms in Study
Posted
August 7, 2025
Views
2,321
Likes
17
Comments
14
Engagement
1.34%
August 7, 2025
2,321
17
14
1.34%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:15Now PlayingEli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday morning, even though the company raised its yearly profit and sales outlook. In the study, patients taking the drug orforglipron, lost roughly 11% of their body weight, about 25 pounds. Bloomberg's Damian Garde reports.
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance
Visit for business news & analysis, uptotheminute market data, features, profiles and more.
Connect with Bloomberg Television on:
Connect with Bloomberg Business on:
More from Bloomberg:
Bloomberg Radio
Bloomberg Surveillance
Bloomberg Politics
Bloomberg Originals
Watch more on YouTube:
Bloomberg Technology
Bloomberg Originals
Bloomberg Quicktake
Bloomberg Espanol
Bloomberg Podcasts
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
